BDNF Levels and Cognitive Function in Patients with Type 2 Diabetes Treated with SGLT2 Inhibitors
Objective: As cognitive impairment becoming more widely recognized as a complication of type 2 diabetes mellitus (T2DM), it is discussed in the literature that antihyperglycemic treatment may also improve cognitive functions. Clinical research on this topic is particularly limited regarding sodium-g...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2025-01-01
|
| Series: | Bezmiâlem Science |
| Subjects: | |
| Online Access: | https://www.bezmialemscience.org/articles/bdnf-levels-and-cognitive-function-in-patients-with-type-2-diabetes-treated-with-sglt2-inhibitors/doi/bas.galenos.2024.38268 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832584747651432448 |
|---|---|
| author | Betül SÜMBÜL ŞEKERCİ Şeymanur DEMİRHAN Esra ÇALIŞICI Abdüsselam ŞEKERCİ |
| author_facet | Betül SÜMBÜL ŞEKERCİ Şeymanur DEMİRHAN Esra ÇALIŞICI Abdüsselam ŞEKERCİ |
| author_sort | Betül SÜMBÜL ŞEKERCİ |
| collection | DOAJ |
| description | Objective: As cognitive impairment becoming more widely recognized as a complication of type 2 diabetes mellitus (T2DM), it is discussed in the literature that antihyperglycemic treatment may also improve cognitive functions. Clinical research on this topic is particularly limited regarding sodium-glucose-cotransporter-2 (SGLT2) inhibitors. Brain-derived neurotrophic factor (BDNF) is a protein essential for cognitive functions and glucose metabolism. The aim of our research was to examine cognitive performance and BDNF levels in users of SGLT2 inhibitors.
Methods: This cross-sectional study was conducted with 86 patients with T2DM, including 41 patients using metformin and 45 patients using SGLT2 inhibitors. Patients’ cognitive performance was assessed with the Montreal cognitive assessment (MoCA) test, and their serum BDNF levels were measured using the ELISA method.
Results: There were no significant differences between SGLT2 inhibitor users and metformin users in MoCA total scores, as well as in the Visuospatial/Executive, Naming, Attention, Language, Abstraction, Memory, and Orientation subdomains. Although BDNF levels were relatively higher in the SGLT2 inhibitor group, the difference was not statistically significant. Significant correlations were observed between BDNF levels and the levels of microalbumin, microalbumin/creatinine, estimated glomerular filtration rate (eGFR), lymphocytes, According to linear regression analysis, effect of eGFR levels in predicting BDNF levels was significant.
Conclusion: Our results indicated that cognitive performance and BDNF levels were similar between users of metformin and SGLT2 inhibitors. Clinical research investigating the effect of SGLT2 inhibitors on cognitive functions in T2DM is limited. Future prospective follow-up studies with SGLT2 inhibitors may provide more comprehensive information. |
| format | Article |
| id | doaj-art-b3dbfea3d130428da48636eaabf51841 |
| institution | Kabale University |
| issn | 2148-2373 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | Bezmiâlem Science |
| spelling | doaj-art-b3dbfea3d130428da48636eaabf518412025-01-27T12:20:16ZengGalenos Publishing HouseBezmiâlem Science2148-23732025-01-01131182410.14235/bas.galenos.2024.38268BDNF Levels and Cognitive Function in Patients with Type 2 Diabetes Treated with SGLT2 InhibitorsBetül SÜMBÜL ŞEKERCİ0https://orcid.org/0000-0001-9970-3491Şeymanur DEMİRHAN1https://orcid.org/0000-0003-3005-3536Esra ÇALIŞICI2https://orcid.org/0009-0005-3359-9261Abdüsselam ŞEKERCİ3https://orcid.org/0000-0002-5849-7545Bezmialem Vakıf University Faculty of Pharmacy, Department of Clinical Pharmacy, Istanbul, TürkiyeMarmara University Institute of Health Sciences, Department of Clinical Pharmacy, Istanbul, TürkiyeBezmialem Vakıf University Faculty of Pharmacy, Istanbul, TürkiyeBezmialem Vakıf University Faculty of Medicine, Department of Internal Medicine, Istanbul, TürkiyeObjective: As cognitive impairment becoming more widely recognized as a complication of type 2 diabetes mellitus (T2DM), it is discussed in the literature that antihyperglycemic treatment may also improve cognitive functions. Clinical research on this topic is particularly limited regarding sodium-glucose-cotransporter-2 (SGLT2) inhibitors. Brain-derived neurotrophic factor (BDNF) is a protein essential for cognitive functions and glucose metabolism. The aim of our research was to examine cognitive performance and BDNF levels in users of SGLT2 inhibitors. Methods: This cross-sectional study was conducted with 86 patients with T2DM, including 41 patients using metformin and 45 patients using SGLT2 inhibitors. Patients’ cognitive performance was assessed with the Montreal cognitive assessment (MoCA) test, and their serum BDNF levels were measured using the ELISA method. Results: There were no significant differences between SGLT2 inhibitor users and metformin users in MoCA total scores, as well as in the Visuospatial/Executive, Naming, Attention, Language, Abstraction, Memory, and Orientation subdomains. Although BDNF levels were relatively higher in the SGLT2 inhibitor group, the difference was not statistically significant. Significant correlations were observed between BDNF levels and the levels of microalbumin, microalbumin/creatinine, estimated glomerular filtration rate (eGFR), lymphocytes, According to linear regression analysis, effect of eGFR levels in predicting BDNF levels was significant. Conclusion: Our results indicated that cognitive performance and BDNF levels were similar between users of metformin and SGLT2 inhibitors. Clinical research investigating the effect of SGLT2 inhibitors on cognitive functions in T2DM is limited. Future prospective follow-up studies with SGLT2 inhibitors may provide more comprehensive information.https://www.bezmialemscience.org/articles/bdnf-levels-and-cognitive-function-in-patients-with-type-2-diabetes-treated-with-sglt2-inhibitors/doi/bas.galenos.2024.38268sodium-glucose transporter 2 inhibitorscognitiontype 2 diabetesbrain-derived neurotrophic factor |
| spellingShingle | Betül SÜMBÜL ŞEKERCİ Şeymanur DEMİRHAN Esra ÇALIŞICI Abdüsselam ŞEKERCİ BDNF Levels and Cognitive Function in Patients with Type 2 Diabetes Treated with SGLT2 Inhibitors Bezmiâlem Science sodium-glucose transporter 2 inhibitors cognition type 2 diabetes brain-derived neurotrophic factor |
| title | BDNF Levels and Cognitive Function in Patients with Type 2 Diabetes Treated with SGLT2 Inhibitors |
| title_full | BDNF Levels and Cognitive Function in Patients with Type 2 Diabetes Treated with SGLT2 Inhibitors |
| title_fullStr | BDNF Levels and Cognitive Function in Patients with Type 2 Diabetes Treated with SGLT2 Inhibitors |
| title_full_unstemmed | BDNF Levels and Cognitive Function in Patients with Type 2 Diabetes Treated with SGLT2 Inhibitors |
| title_short | BDNF Levels and Cognitive Function in Patients with Type 2 Diabetes Treated with SGLT2 Inhibitors |
| title_sort | bdnf levels and cognitive function in patients with type 2 diabetes treated with sglt2 inhibitors |
| topic | sodium-glucose transporter 2 inhibitors cognition type 2 diabetes brain-derived neurotrophic factor |
| url | https://www.bezmialemscience.org/articles/bdnf-levels-and-cognitive-function-in-patients-with-type-2-diabetes-treated-with-sglt2-inhibitors/doi/bas.galenos.2024.38268 |
| work_keys_str_mv | AT betulsumbulsekerci bdnflevelsandcognitivefunctioninpatientswithtype2diabetestreatedwithsglt2inhibitors AT seymanurdemirhan bdnflevelsandcognitivefunctioninpatientswithtype2diabetestreatedwithsglt2inhibitors AT esracalisici bdnflevelsandcognitivefunctioninpatientswithtype2diabetestreatedwithsglt2inhibitors AT abdusselamsekerci bdnflevelsandcognitivefunctioninpatientswithtype2diabetestreatedwithsglt2inhibitors |